Orthocell Ltd

As of June 30, 2026, Orthocell Ltd carries a market capitalization of 197.38M, placing it among publicly traded companies globally. Its enterprise value stands at 154.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Orthocell Ltd's next confirmed earnings release is scheduled for February 19, 2027.

As of June 30, 2026, Orthocell Ltd has 272.25M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 16.74, and the price-to-book ratio stands at 5.74.

These figures are as of June 30, 2026. The EV/Sales ratio of 13.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 154.40M versus a market cap of 197.38M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Orthocell Ltd maintains a current ratio of 5.97, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Orthocell Ltd posted a negative return on equity (ROE) of -56.82, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -30.91, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Orthocell Ltd's stock has declined approximately 59.30% over the past 52 weeks. The 50-day moving average sits at 0.73, while the 200-day moving average is 0.81.

Over the twelve months ended June 30, 2026, Orthocell Ltd generated 11.41M in revenue and converted that into -13.91M in net income, yielding earnings per share of -0.05. EBITDA reached -18.38M, while operating income came in at -19.10M.

As of June 30, 2026, Orthocell Ltd holds 43.95M in cash and equivalents against 970,192.00 in total debt, resulting in a net debt position of -43.95M. Total book value stands at 34.41M, with working capital of 41.46M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -167.46 and net profit margin of -121.98 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -15.47, meaning Orthocell Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Orthocell Ltd has an Altman Z-Score of 3.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.